Neurocrine Biosciences (NBIX) EBITDA Margin (2009 - 2026)
Neurocrine Biosciences (NBIX) reported EBITDA Margin of 33.43% for Q3 2026, up 2.39 percentage points from 31.04% a year earlier and up 15.04 percentage points from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EBITDA Margin (2009 - 2026) Analysis & Trends
Over the twelve months ended Sep 30, 2026, Neurocrine Biosciences' EBITDA Margin came in at 26.22%, up 4.61 percentage points year-over-year; for FY2025, it was 22.70%, down 2.68 percentage points from FY2024.
- EBITDA Margin has a five-year change of +4.38 percentage points (FY2020 to FY2025).
- By year, EBITDA Margin came in at 25.37% in FY2024 (+10.91 pp), 14.46% in FY2023 (-3.39 pp), 17.85% in FY2022 (+6.42 pp) and 11.43% in FY2021 (-6.89 pp).
- The Q3 2026 figure ranks as the highest quarterly EBITDA Margin since Q3 2019.
- Year over year, EBITDA Margin gained in four of the last eight quarters, with an average year-over-year change of -0.46 percentage points.
- The high point for year-over-year EBITDA Margin in five years was Q1 2024 (a gain of 46.40 percentage points); the low point was Q4 2021 (a drop of 41.15 percentage points).
- Per Business Quant data, the three quarters before Q3 2026 came in at 18.38% (Q2 2026), 24.64% (Q1 2026) and 27.11% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn | 33.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 33.43% |
| Jun 30, 2026 | 18.38% |
| Mar 31, 2026 | 24.64% |
| Dec 31, 2025 | 27.11% |
| Sep 30, 2025 | 31.04% |
| Jun 30, 2025 | 22.24% |
| Mar 31, 2025 | 5.45% |
| Dec 31, 2024 | 23.75% |
| Sep 30, 2024 | 30.59% |
| Jun 30, 2024 | 25.87% |
| Mar 31, 2024 | 20.47% |
| Dec 31, 2023 | 30.30% |
| Sep 30, 2023 | 29.45% |
| Jun 30, 2023 | 17.43% |
| Mar 31, 2023 | -25.93% |
| Dec 31, 2022 | 26.21% |
| Sep 30, 2022 | 23.72% |
| Jun 30, 2022 | 15.60% |
| Mar 31, 2022 | 2.19% |
| Dec 31, 2021 | -9.36% |
API Access
Neurocrine Biosciences EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();